Infrared Low-Level Laser Therapy (Photobiomodulation Therapy) before Intense Progressive Running Test of High-Level Soccer Players: Effects on Functional, Muscle Damage, Inflammatory, and Oxidative Stress Markers—A Randomized Controlled Trial

Table 3

Outcomes (values are expressed as mean and standard deviation).

		Baseline	Postexercise
VO2 max relative (l/kg·min)	Placebo PBMT; Active PBMT	—	55.69 (±5.55); 59.40 (±5.08)^a
VO2 max absolute (l/min)	Placebo PBMT; Active PBMT	—	3.57 (±0.60); 4.02 (±0.41)^a
Time until exhaustion (s)	Placebo PBMT; Active PBMT	—	504.59 (±160.44); 563.27 (±159.46)^a
Anaerobic threshold (s)	Placebo PBMT; Active PBMT	—	384.86 (±63.53); 440.73 (±58.58)^a
Anaerobic threshold (l/min)	Placebo PBMT; Active PBMT	—	2.93 (±0.46); 3.26 (±0.40)^b
Aerobic threshold (s)	Placebo PBMT; Active PBMT	—	169.73 (±45.40); 184.36 (±44.84)
Aerobic threshold (l/min)	Placebo PBMT; Active PBMT	—	2.20 (±0.43); 2.53 (±0.29)^a
CK (U·l^-1)	Placebo PBMT; Active PBMT	201.76 (±32.98); 215.61 (±37.22)	372.43 (±29.11); 282.03 (±33.26)^c
LDH (U·l^-1)	Placebo PBMT; Active PBMT	290.02 (±41.82); 302.13 (±46.73)	483.55 (±38.09); 378.97 (±41.52)^c
IL-1β (pg/ml)	Placebo PBMT; Active PBMT	2.98 (±0.56); 3.19 (±0.62)	3.37 (±0.61); 3.40 (±0.54)
IL-6 (pg/ml)	Placebo PBMT; Active PBMT	33.92 (±6.09); 30.6 (±5.89)	54.08 (±5.56); 42.77 (±6.01)^c
TNF-α (pg/ml)	Placebo PBMT; Active PBMT	57.81 (±8.75); 60.04 (±9.03)	63.99 (±9.87); 65.34 (10.71)
TBARS (nmol/ml)	Placebo PBMT; Active PBMT	3.42 (±0.85); 3.71 (±0.79)	5.74 (±0.78); 3.94 (±0.71)^c
Carbonylated proteins (nmol of DNPH/g/dl of protein)	Placebo PBMT; Active PBMT	2.07 (±0.67); 2.00 (±0.63)	2.98 (±0.70); 2.34 (±0.59)^a
SOD (U SOD/g of protein)	Placebo PBMT; Active PBMT	2.98 (±0.65); 2.82 (±0.55)	1.99 (±0.86); 3.23 (±0.91)^c
CAT (U CAT/g of protein)	Placebo PBMT; Active PBMT	2.81 (±0.73); 2.73 (±0.66)	2.04 (±0.75); 3.24 (±0.83)^c

^aDifference of placebo PBMT (). ^bDifference of placebo PBMT (). ^cDifference of placebo PBMT ().